FDA Approves Expanded Liquid Biopsy Panel - Summary - MDSpire

FDA Approves Expanded Liquid Biopsy Panel

Updated liquid biopsy combines genomic and epigenomic profiling for companion diagnostic use across multiple tumor types.

  • By

  • Kathryn Wighton

  • May 20, 2026

  • 2 min

Share

Objective:

To inform about the FDA approval of the Guardant360 Liquid CDx assay for advanced cancer treatment selection.

Key Findings:
  • The assay is the largest FDA-approved liquid biopsy panel.
  • It combines genomic and epigenomic profiling to improve tumor detection.
  • The platform is based on AI-enabled technology and supports various cancer care stages.
Interpretation:

This approval signifies a significant advancement in precision oncology, providing clinicians with timely and comprehensive information for treatment decisions.

Limitations:
  • The assay's effectiveness may vary based on individual patient factors.
  • Coverage by insurers may not be universal across all regions.
Conclusion:

The Guardant360 Liquid CDx assay represents a major step forward in liquid biopsy technology, potentially improving treatment outcomes for patients with advanced cancers.

Original Source(s)

FDA Approves Expanded Liquid Biopsy Panel

  • by Kathryn Wighton

  • May 20, 2026

Related Content

AI May Improve Breast Mitotic Scoring

Junior pathologists showed higher mitotic score accuracy and agreement with artificial intelligence assistance in a preliminary single-center reader study

AI Outperforms MDs on Reasoning Tasks

Across six experiments—including a blinded, real-world ER evaluation—an OpenAI large language model outperformed physician baselines on multiple clinical reasoning tasks, though not on key safety endpoints such as cannot-miss diagnoses

Digital Twin Model May Improve Alcohol Intake Reconstruction

Integrated biomarker framework supports evaluation of drinking scenarios in forensic settings